Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007120 | 0.86 | GSK3B (0.69) | GSK3BAXLPDPK1AURKAROCK1 | |
| SCHEMBL13868958 | 0.81 | GSK3B (0.77) | GSK3BAXLPDPK1AAK1DYRK1A | |
| SCHEMBL14942621 | 0.80 | ITK (0.47) | GSK3BDYRK1AMAP2K4 | |
| SCHEMBL2927184 | 0.79 | DYRK1A (0.69) | GSK3BAAK1DYRK1A | |
| SCHEMBL2261204 | 0.79 | DYRK1A (0.65) | GSK3BAXLPDPK1DYRK1AAURKB | |
| SCHEMBL31032803 | 0.79 | MAP2K4 (0.62) | GSK3BTRPA1MAP2K4 | |
| SCHEMBL12292284 | 0.79 | DYRK1A (0.42) | GSK3BDYRK1ATRPA1MAP2K4 | |
| SCHEMBL18410601 | 0.78 | TRPA1 (0.53) | GSK3BAXLPDPK1AURKATGFBR1 | |
| SCHEMBL922069 | 0.77 | PDPK1 (0.65) | AXLPDPK1AURKATGFBR1ROCK1 | |
| SCHEMBL12365607 | 0.76 | GSK3B (0.49) | GSK3BAXLPDPK1DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | GSK3B 36/4885AXL 906/4885PDPK1 222/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | GSK3B 36/4885AXL 906/4885PDPK1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.